Post-Market Study to Assess Outcomes of Patients Treated With AFX System Compared to Other EVAR Devices

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 455 participants.

Also called NCT02407457

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 455 participants (enrolled count) (from the registry)
Sponsor
  • Endologix Registry lists this organization as the lead sponsor
Registry
  • NCT NCT02407457
Other papers using this trial's data
  • Five-year results of the LEOPARD trial of commercially available endografts Journal of vascular surgery, 2023-08 DOI, PubMed 37068528

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02407457. Randomized; no masking; primary purpose treatment. Start 2015-03 (actual); primary completion 2018-10 (actual). Results posted on 2020-09-21.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Post-Market Study to Assess Outcomes of Patients Treated With AFX System Compared to Other EVAR Devices
Acronym
LEOPARD
Condition
Abdominal Aortic Aneurysm
Intervention (Device)
AFX EVAR AAA Graft System
Intervention (Device)
FDA Approved EVAR AAA Graft Systems
Lead sponsor
Endologix (class: industry)

Record details

Record id
cardio:ct-nct02407457
Content hash
c7018788a15d2c94f85e8c6bde978d582b4a82c3604841d803d47775483e0099